Share Forum - Discuss JSE shares and join the Investor Challenge

Do you see this stock going beyond R10?

       The Sunwave Transaction and the NHP Pharma Transaction are collectively referred to as
       the “Proposed Transactions” for the purpose of this announcement.
       Sunwave is a distributor of complementary and alternative medicines (“CAMS”) and food
       supplement products in Romania. It is the largest player in the food supplements category
       and sixth largest player in the broader over-the-counter (“OTC”) category in the country. The
       company specialises in marketing its products directly to the doctor community, through a
       sales force of approximately 290 effective and well-trained individuals.
       NHP Pharma, in collaboration with its third-party suppliers, has developed a vast product
       portfolio of complementary medicines across nine major therapeutic areas. The efficacy of its
       products have been further validated through clinical and post-marketing studies. NHP
       Pharma owns the trademarks and other relevant IP relating to its products, with Sunwave
       being NHP Pharma’s largest customer.
       The Proposed Transactions are inter-conditional and, going forward, will be treated as a
       single business combination in the hands of Ascendis. Ascendis aims to achieve an EBITDA
       margin of approximately 20% from the Proposed Transactions.